Recently, it was reported that anti‐EGFR antibodies do not have survival benefit for RAS wild‐type right‐side colon cancer.50, 51 However, the shrinkage of tumor is adequate even in right‐side colon cancer.52, 53 Therefore, anti‐EGFR antibodies should be used cautiously for right‐side RAS wild‐type CRLM. This evidence concerns the gene EGFR and colonic neoplasm.